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Abstract
Background: Desmoid tumour is a benign, non metastasising neoplasm characterised by an
elevated deposition of organic macromolecules in the extracellular matrix (ECM). The matrix
metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation
of ECM macromolecules. The MMPs and their natural inhibitors (TIMPs) have been implicated in
tumour growth, invasion and metastasis. In this study we provide evidence that the in vitro cultured
cell line from desmoid tumour accumulates more collagen fibres in the ECM than healthy
fibroblasts.
Methods: We investigated collagen accumulation by 3H-thymidine incorporation, MMP
expression by substrate gel zymography and TIMP expression by Western blot analysis.
Results: Desmoid fibroblasts showed a reduction in MMP activity and an increase of type I and III
collagen and TIMPs compared to normal fibroblasts.
Conclusion: The increase in collagen in desmoid fibroblasts was due to inhibited collagen
degradation (reduction of MMP activity) rather than to increased collagen synthesis. Adding
toremifene, an anti-estrogen triphenylethylene derivate, to desmoid fibroblasts reduced collagen
accumulation by decreasing mRNA expression and increasing collagen degradation.
Background
Desmoid tumours, which are frequently observed in
Gardner's syndrome, are rare, slow-growing, histologi-
cally benign tumours caused by autosomal dominant
gene mutation [1,2]. They are, however, locally aggressive,
compress surrounding structures and show frequent
recurrences after surgical removal. Desmoid cells are char-
acterized by abundant deposition of organic macromole-
cules in the extracellular matrix (ECM), by enhanced
transforming growth factor β1 (TGFβ1) gene expression
and increased protein secretion [3]. Cell proliferation,
angiogenesis and the accumulation of ECM macromole-
cules are all facilitated by tumour cell production of
TGFβ1 [3-6]. All components of ECM are degraded by
matrix metalloproteinases (MMPs), a family of zinc-
dependent neutral endopeptidases [7]. Two types of
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collagenases and gelatinases [8]. Collagenase-1 (MMP-1),
collagenase-2 (MMP-8) and collagenase-3 (MMP-13) are
the principal secreted neutral proteinases that initiate deg-
radation of native fibrillar collagens of type I, II, III and V.
They all cleave fibrillar collagens at a specific site, resulting
in the generation of N-terminal 3/4 and C-terminal 1/4
fragments, which are further degraded by gelatinases
[7,9,10]. Gelatinase-A (MMP-2) is expressed by several
types of cells, especially fibroblasts, whereas gelatinase-B
(MMP-9) is restricted to epithelial cells. MMP-2 and
MMP-9 are thought to play major roles in the final degra-
dation of fibrillar collagens after first cleavage by colla-
genases and denaturation [11]. MMP-2 also cleaves native
type I collagen to N-terminal 3/4 and C-terminal 1/4 frag-
ments which are identical to those generated by colla-
genases [12]. Several different tissue inhibitors of matrix
metalloproteinases (TIMPs; TIMP-1 to TIMP-4) have been
identified as the major natural inhibitors of MMPs [13].
TIMP-1 and TIMP-2 inhibit the activity of most MMPs
[11]. Expression of TIMP-1 is up-regulated at the tran-
scription level by various growth factors such as TGFβ1,
whereas TIMP-2 is largely expressed constitutively by cul-
tured cells [14]. Our previous studies showed desmoid
fibroblasts enhanced deposition of organic macromole-
cules in the ECM and TGFβ1 secretion [3]. Even if desmoid
cells do not have estrogen receptors [3], adding
toremifene, an antiestrogenic triphenylethylene derivate,
decreased TGFβ1 production and ECM macromolecule
accumulation through a mechanism of action that still
remains unclear [3,6,15,16]. The present study investi-
gates the rule of MMPs and TIMPs in the desmoid tumour
and describes, for the first time, the effects of toremifene
on MMPs and TIMPs. The results provided evidence that
toremifene reduced ECM accumulation by decreasing col-
lagen synthesis and increasing collagen degradation.
Methods
Antiestrogen
Toremifene (4-chloro-1,2-diphenyl-1-{4-[2-(N,N-
dimethylamino) ethoxy] phenyl}-1-butene) citrate was
purchased from Farmos (Farmos Group Ltd, Finland).
Cell cultures
Fibroblast cell lines were obtained from patients with
Gardner's syndrome and were provided by NIGMS (Cam-
den, N.J.). The GMO 6965 cell line was obtained from
phenotypically healthy fibroblasts, and the GMO 6888
cell line was obtained from desmoid fibroblasts. All cell
lines were cultured in Eagle's minimal essential medium
(MEM) (Sigma, St. Louis, MO) supplemented with 20%
fetal bovine serum (FBS) (GIBCO-Invitrogen, Basel, Swit-
zerland), 2% non-essential amino acids (GIBCO), 2 mM
L-glutamine, 100 U/ml penicillin and 100 U/ml strepto-
mycin in a humidified 5% CO2 atmosphere at 37°C. Con-
fluent cultures were obtained after 48 h of in vitro
maintenance. The cells were cultured for 12 h in MEM.
The medium was then discarded to avoid serum factor
contamination. Toremifene was dissolved in ethanol and
all the cultures were maintained in MEM containing etha-
nol or MEM containing toremifne in ethanol and treated
as described below.
Cell viability
Normal (control) and desmoid fibroblasts were cultured
for 24 h in MEM and ethanol or MEM containing 1 µM
toremifene in ethanol (final concentration 0.1% v/v).
Then 50 µl of sterile 0.4% trypan blue solution (final con-
centration 0.05%) was added to each culture well; cul-
tures were incubated at 37°C for 15 min. Viable cells
(trypan blue negative) and dead cells (trypan blue posi-
tive) were counted by a Burker chamber.
Collagen synthesis
Confluent cultures of normal (GMO 6965) and desmoid
fibroblasts (GMO 6888) were cultured for 3, 24 and 48 h
in MEM without serum supplemented L-ascorbic acid (50
µg/ml), β-aminopropionitrile fumarate (50 µg/ml), 8
µCi/ml of 3H-proline (specific activity 35 Ci/mmole,
Amersham, Freiburg, Germany) in the presence or
absence of 1 µM toremifene. In a second set of experi-
ments desmoid fibroblasts were cultured in MEM supple-
mented with L-ascorbic acid (50 µg/ml), β-
aminopropionitrile fumarate (50 µg/ml) for 48 h with or
without toremifene. 3H-proline was added for 48 h, for
the last 24 and for the last 3 h. At the end of the labelling
period collagen was extracted using the method of Web-
ster and Harvey [17]. Samples were digested with pepsin
(1 mg/ml) in mild agitation overnight at 4°C. Collagen
was precipitated and redissolved in 500 µl cold acetic acid
0.5 M. Total radioactivity was counted in a liquid scintil-
lation counter and expressed as cpm/µg protein.
Northern blot analysis of procollagen α1 (I)
Total RNA was isolated from confluent cultures of normal
and desmoid fibroblasts maintained for 48 h in MEM
alone or supplemented with 1 µM toremifene using the
method of Chomczynski and Sacchi [18]. For Northern
blot analysis equal amounts of total RNA (20 µg) were
electrophoresed on 1% agarose gel containing 0,66 M for-
maldehyde and transferred on to nylon filters (Hybond N,
Amersham). Before blotting, the gel was rinsed in water
for 15 min at room temperature and then in 20X SSC (1 X
SSC is 0.15 M sodium chloride, 0.015 M sodium citrate,
pH 7) for 10 min. Blots were pre-hybridised in 20 ml of a
cocktail containing 1 mM EDTA pH 8, 0.25 M Na2HPO4
pH 7.2 and 7% sodium dodecyl sulfate (SDS) for 4 h at
65°C. Probes were labelled with [α-32P] dCTP (3000 Ci/
mM) by random priming (Amersham RPN 1601).
Hybridisation was performed at 65°C overnight usingPage 2 of 14
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isation. After hybridisation, the nylon membrane was
washed twice in 1 mM EDTA pH 8, 20 mM Na2HPO4 pH
7.2 and 5% SDS at 65°C (5 min each) and then washed
twice with 1 mM EDTA pH 8, 20 mM Na2HPO4 pH 7.2
and 1% SDS at 65°C (5 min each). The filters were
stripped and re-hybridised with a GAPDH probe to assess
blot loading. For autoradiography the membranes were
exposed to Kodak X-Omat film (Rochester, NY) at -80°C
for 1 day. Autoradiographies were analysed by computer-
ised scanning densitometry. Results are expressed as the
ratio of procollagen α1(I)/control GAPDH densitometry
signals.
cDNA probes
A 670 bp Eco RI-Hind III cDNA fragment from human
pro-collagen α1(I) and a 1.3 kb PstI cDNA fragment from
rat glyceraldehyde-3-phosphate dehydrogenase were used
as probes in hybridisation [18].
Collagenase activity
Collagenase activity was determined using the method of
Khorramizadeh et al., [19]. Confluent normal and
desmoid fibroblasts were washed with MEM and cultured
for 48 h in MEM or in MEM containing 1 µM toremifene.
Proteins in the medium were precipitated by ammonium
sulphate 65% w/v; precipitates were collected by centrifu-
gation, dissolved in assay buffer (0.05 M Tris-HCl, 0.2 M
NaCl, 5 mM CaCl2, 0.02% sodium azide, pH 7.4) and
then dialysed overnight against the same buffer. The
latent procollagenase was activated with trypsin (10 µg/
ml) and then the trypsin was inactivated with soybean
trypsin inhibitor (100 µg/ml). Acetic acid soluble type I
collagen (25 µl of a solution 2 mg/ml) from bovine skin
was incubated with the activated collagenase solution for
24 h. The products of the collagen digestion were sepa-
rated by electrophoresis using 6% acrylamide gel contain-
ing SDS. The gels were stained with 0.25% Coomassie
brilliant blue G-250 (50% methanol, 10% acetic acid),
destained appropriately (40% methanol, 10% acetic acid)
and fixed (5% methanol, 7.5% acetic acid). The digestion
products were quantified with a computerised scanner.
Preparation of conditioned media (CM)
Confluent normal (GMO 6965) and desmoid (GMO
6888) fibroblasts were washed with 0.9% NaCl and cul-
tured for 12 h in serum-free MEM. This medium was dis-
carded to avoid contamination by serum factors and cells
were cultured for the next 24 h in MEM and ethanol (con-
trol) or in MEM containing 1 µM toremifene in ethanol
(final ethanol concentration 0.1% v/v). Conditioned
media (CM) were collected and centrifuged for 10 min at
350 g to remove cell debris, dialysed against bidistilled
water for 24 h, lyophilised and used for zymography and
Western blot analysis as described below.
Collagen and gelatin zymography
CM were analysed for gelatinases and collagenases by
zymography. Samples were separated under non reducing
condition on 6% polyacrylamide gels containing 1 mg/ml
of gelatin (Sigma Chemical, St Louis; MO, USA) or 1 mg/
ml collagen (Sigma) [20]. In one set of samples the proen-
zymatic forms were activated using 2 mM aminophe-
nylmercuric acetate (APMA) for 1 h at 37°C. Samples
were lyophilised and resuspended in Tris-HCl 0.4 M pH
6.8, SDS 5%, 20% glycerol and 0.03% bromophenol blue.
Gels were loaded with 8 µg protein per sample or with 2
µg trypsin and run under Laemmli conditions [21]. After
electrophoresis, gels were washed twice in 200 ml of 2.5%
Triton X-100 (30 min each) under constant mechanical
stirring and incubated in 50 mM Tris-HCl pH 7.5, 5 mM
CaCl2, 0.02% Brij-35 and 200 mM NaCl at 37°C for 24 h.
Gels were stained with Coomassie brilliant blue G-250.
Proteinase activity, observed as cleared (unstained)
regions, was converted to dark regions to better observa-
tion of bands.
Western-blot analysis
CM were analysed for type I and type III collagen, MMP-
1, MMP-2, MMP-9, TIMP-1 and TIMP-2 by Western blot-
ting using specific monoclonal antibodies. Aliquots of
CM, containing 50 µg of proteins, were separated on SDS-
10% polyacrylamide gels under reducing conditions and
transferred on to a nitrocellulose membrane. The mem-
brane was blocked with blocking solution (5% w/v dried
skimmed-milk powder in TBS 1X, 2 h at room tempera-
ture) and incubated with the specific monoclonal anti-
body in antibody solution (1% w/v dried skimmed-milk
powder in TBS 1X, 2 h at room temperature). Bound anti-
body was detected with a sheep anti-mouse peroxidase-
conjugated antibody in antibody solution. Western anal-
ysis was performed using chemiluminescence reagents
from Amersham Pharmacia Biotech.
Protein determination
Protein concentrations were determined by the Lowry
assay [22] of aliquots of cell lysate.
Statistical analysis
In some experiments, statistical analysis was performed
using Student's t-test. Data are expressed as the means ±
SD of four determinations. In other experiments, the
results are reported as means ± SD of three separate exper-
iments, each performed in quadruplicate. Statistical anal-
ysis was performed by Student's two-tailed t-test and by
analysis of variance (ANOVA) followed by Sheffe F-test.
Results
Cell viability
The amount of dead cells and viable cells in normal
fibroblasts, desmoid fibroblasts and desmoid fibroblastsPage 3 of 14
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tenance in the presence of trypan blue (Table 1). Granted
that the number of intact viable cells was high in all the
experimental conditions, desmoid fibroblasts had the
highest number of cells/culture and the lowest percentage
of dead cells (0.0014%). Treatment of desmoid fibrob-
lasts with toremifene enhanced the percentage of dead
cells (0.011%) which, nevertheless, remained lower than
in normal fibroblasts (0.025%.).
Effects of toremifene on collagen synthesis
Collagen synthesis was evaluated after 3, 24 and 48 h of
in vitro maintenance in the presence of 3H-proline (Table
2). No significant difference was observed after 3 hours
culture. After 24 and 48 h culture collagen production was
significantly higher in desmoid than in normal fibrob-
lasts, in both the cellular and extracellular compartments.
The increase was 1.4 fold in the cells and 1.8 fold in the
medium after 24 h; 1.3 fold in the cells and 1.8 fold in the
medium after 48 h. Adding toremifene significantly
decreased collagen synthesis at 24 and at 48 h. The reduc-
tion was greater after 48 h (42% in the cells and 38% in
the medium). In a second set of experiments desmoid
fibroblasts were cultured for 48 h with or without
toremifene. The radiolabelled precursor was added for 48
h, in the last 24 h and in the last 3 h (Table 3). Treatment
with toremifene had an inhibitory effect at all times. The
decrease in total collagen (cells + media) in desmoid
fibroblasts treated with toremifene was 28% in the pres-
ence of 3H-proline for 48 h, 46% and 52% respectively in
the presence of 3H-proline in the last 24 or 3 h of in vitro
maintenance (Table 3).
Table 1: Cell viability
Viable cells Dead cells % of dead cells
Normal fibroblasts 1,224,805 ± 56,280 308 ± 26 0.025
Desmoid fibroblasts 1,636,710 ± 84,105* 29 ± 4 0.0017
Desmoid fibroblasts + toremifene 1,393,900 ± 86,400 161 ± 15 0.011
Fibroblasts were cultured for 24 h in MEM containing ethanol with or without toremifene. Number of viable and dead cells/culture after exposure 
to trypan blue for 15 min. The values are the means ± SD of five cultures. *Significance vs normal fibroblasts: P < 0.01.
Table 2: 3H-proline incorporation into collagen fibres
Cells Media
3 h
Normal fibroblasts 1,060 ± 85 998 ± 94
Desmoid fibroblasts 885 ± 60 991 ± 39
Desmoid fibroblasts + toremifene 1,112 ± 134 837 ± 36
24 h
Normal fibroblasts 2,313 ± 99 6,523 ± 388
Desmoid fibroblasts 3,340 ± 205* 11,641 ± 421*
Desmoid fibroblasts + toremifene 2,286 ± 124°° 9,962 ± 644°°
48 h
Normal fibroblasts 4,262 ± 280 17,955 ± 1,073
Desmoid fibroblasts 5,649 ± 103* 32,988 ± 1,321*
Desmoid fibroblasts + toremifene 3,295 ± 261° 20,407 ± 980°
Fibroblasts were cultured for 3, 24 and 48 h in MEM containing 3H-proline with or without toremifene. Total radioactivity value is expressed in 
cpm/mg protein and represents the mean ± SD of three determinations, each in quadruplicate. The statistical analysis was performed with analysis 
of variance (ANOVA). Differences vs normal fibroblasts: F-test significant at *99%; differences vs desmoid fibroblasts: F-test significant at °99%, 
°°95%.Page 4 of 14
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Northern blots were performed to analyse procollagen α1
(I) mRNA level in normal and desmoid fibroblasts (Fig.
1). Relative densitometric units were normalised to
GAPDH mRNA levels. Normal and desmoid fibroblasts
exhibited no significant differences in the steady-state
mRNA levels for procollagen α1 (I). Toremifene down reg-
ulated procollagen mRNA expression by 58% in desmoid
cells.
Western-blot analysis of type I and III collagen
Media from normal and desmoid fibroblasts with or with-
out toremifene were analysed by Western blotting to eval-
uate the presence of type I and III collagen using specific
monoclonal antibodies (Fig. 2). Densitometric tracing of
the autoradiograms quantified collagen secretion.
Desmoid fibroblasts secreted much more type I (1.6 fold)
and III (2.2 fold) collagen than normal cells. Toremifene
reduced type I and III collagen by 31% and 18% respec-
tively in desmoid fibroblasts.
Collagenase activity
Collagenases, from ammonium sulphate-precipitated
proteins of media of normal fibroblasts, desmoid fibrob-
lasts and desmoid fibroblasts treated with toremifene,
were incubated with soluble collagen and the digested
products were evaluated by gel electrophoresis. Colla-
genases in the medium of normal fibroblasts digested
more α1 and α2 chains of type I collagen into their corre-
sponding 3/4 and 1/4 fragments than the collagenase in
desmoid fibroblasts (Fig. 3). When band staining inten-
sity was quantified by densitometry, the abundance of the
3/4 and 1/4 products of collagenase digestion was signifi-
cantly greater in normal than in desmoid fibroblasts. Add-
ing toremifene to desmoid fibroblasts markedly increased
collagenase activity as shown by the increased amount of
3/4 and 1/4 fragments of α1 and α2 chains (Fig. 3).
Collagen and gelatin zymography
Collagen and gelatin zymograms dosed the enzymatic
activity of collagenases and gelatinases. Collagen zymo-
gram, reported in Fig. 4 (panel A and B), showed the sam-
ples produced a band of 52 kDa corresponding to MMP-
1. Densitometric analysis of the counts, assuming the
value of normal fibroblasts as 100%, demonstrated 2.3
fold increase in the 52 kDa collagenase activity in
desmoid fibroblasts. When desmoid fibroblasts were
treated with toremifene, the level of collagenase activity in
the media was only minimally affected. No bands were
present in trypsin (Fig. 4, panel A, line C), which can
degrade gelatin but not collagen, confirming that collagen
has been degraded in panel A. The gelatin zymogram (Fig.
4, panel C and D) showed two bands, one of 92 kDa cor-
responding to MMP-9, the other of 66 kDa corresponding
to MMP-2. Desmoid fibroblasts produced the same
amount of MMP-9, and larger (about 2 fold) amounts of
MMP-2, than normal fibroblasts Adding toremifene to
desmoid fibroblasts increased only MMP-2 activity by
about 1.32 fold. To verify whether the bands detected in
the collagen and gelatin zymography were due only to
MMPs, two control gels were washed and incubated in
buffers containing 10 mM EDTA. No bands were detected
after this treatment, which indicated that the bands
obtained in collagen and gelatin zymographies were
entirely due to MMP activity. Toremifene addition to
desmoid cells was accompanied by no changes in gelati-
nase activity. One set of samples in collagen and gelatin
zymograms was treated with APMA to activate the proen-
zymes. Activation of the proenzymatic form had no signif-
icant effects on collagenase activity (Fig. 4, panel B), but
Table 3: 3H-proline incorporation into collagen fibres
Cells Media Cells + Media
48 h
Desmoid fibroblasts 6,852 ± 290 33,915 ± 2,307 40,767
Desmoid fibroblasts + toremifene 4,243 ± 361* 25,097 ± 814* 29,340
24 h
Desmoid fibroblasts 4,252 ± 416 15,423 ± 1,100 19,675
Desmoid fibroblasts + toremifene 1,432 ± 101* 9,221 ± 381* 10,653
3 h
Desmoid fibroblasts 1,176 ± 48 1,498 ± 56 2,674
Desmoid fibroblasts + toremifene 534 ± 31* 745 ± 74* 1,279
Fibroblasts were cultured for 48 h in MEM with or without toremifene. 3H-proline was added for 48 h, for the last 24 h and for the last 3 h. Total 
radioactivity value is expressed in cpm/mg protein and represents the mean ± SD of three determinations, each in quadruplicate. The statistical 
analysis was performed with analysis of variance (ANOVA). Differences vs desmoid fibroblasts: F-test significant at *99%.Page 5 of 14
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4, panel D).
Western-blot analysis of MMP-1, MMP-2, MMP-9
The presence of MMP-1, MMP-2, MMP-9 in the media of
normal fibroblasts, desmoid fibroblasts and desmoid
fibroblasts plus toremifene was evaluated by Western-blot
analysis using specific monoclonal antibodies (Fig. 5).
Western blot analysis of MMP-1 (Fig. 5, panel A) showed
that the amount of the protein was higher in desmoid (2
fold) and in desmoid than in normal fibroblasts (2 fold).
Toremifene exhibited no significant increase of MMP-1 in
desmoid cells (about 2.2 fold). MMP-2 (Fig. 5, panel B)
showed two bands, the first due to the proenzymatic form
(72 kDa) and the second to the active form (66 kDa).
MMP-2 was significantly increased in desmoid fibroblasts
(2.2 fold) and even more in desmoid fibroblasts plus
Expression of procollagen α1 (I) and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA in normal and desmoid fibroblastsFigure 1
Expression of procollagen α1 (I) and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA in normal 
and desmoid fibroblasts. Panel A: NF: normal fibroblasts; DF: desmoid fibroblasts; DFT: desmoid fibroblasts plus 
toremifene. Similar results were obtained in four separate experiments. In panel B the absolute counts, obtained by densito-
metric analysis, were converted to percentages of control value, assuming the untreated level of normal fibroblasts as 100%.
A. 
NF DF DFT 
                                                         
B.        
       
Pro-collagen α1 (I)/GAPDH
Normal fibroblasts 100
Desmoid fibroblasts 106 
Desmoid fibroblasts plus toremifene 44 
Pro α1(I)             5.8 kb - 
                           4.7 kb -
GAPDH              1.3 kb - Page 6 of 14
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BMC Cancer 2005, 5:22 http://www.biomedcentral.com/1471-2407/5/22Western blot analysis of type I and III collagen secreted into the medium by normal and desmoid fibroblastsFigure 2
Western blot analysis of type I and III collagen secreted into the medium by normal and desmoid fibroblasts. 
Panel A. The samples are as follow: NF normal fibroblasts; DF desmoid fibroblasts; DFT desmoid fibroblasts plus toremifene. 
Similar results were obtained in four separate experiments. Panel B. The absolute counts, obtained by densitometric analysis, 
were converted to percentages assuming the level of normal fibroblasts as 100%.
A. 
NF DF DFT 
NF DF DFT 
B. 
Type I collagen Type III collagen 
Normal fibroblasts 100 100
Desmoid fibroblasts 161 220 
Desmoid fibroblasts plus toremifene 110 181 
Type I collagen    95 kDa→
Type III collagen    110 kDa→Page 7 of 14
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Collagenase activity in media derived from normal, desmoid fibroblasts and desmoid fibroblasts plus 
toremifene. Panel A. NF: normal fibroblasts; DF: desmoid fibroblasts; DFT: desmoid fibroblasts plus toremifene. Similar 
results were obtained in four separate experiments. In panel B the quantity of 3/4 and 1/4 fragments of digested collagen was 
determined by densitometric analysis. The absolute counts were converted to percentages assuming the level of normal fibrob-
lasts as 100%.
A. 
NF DF DFT 
  
B. 
Normal 
fibroblasts 
Desmoid 
fibroblasts 
Desmoid 
fibroblasts plus 
toremifene 
α1 (3/4) fragments 100 22 80 
α1 (1/4) fragments 100 25 75 
α1→
α2→
α1(3/4) fragments→
α1(1/4) fragments→Page 8 of 14
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BMC Cancer 2005, 5:22 http://www.biomedcentral.com/1471-2407/5/22Zymogram of media from normal fibroblasts, desmoid fibroblasts, desmoid fibroblasts plus toremifeneFigure 4
Zymogram of media from normal fibroblasts, desmoid fibroblasts, desmoid fibroblasts plus toremifene. Colla-
gen zymogram. One set of samples was treated with APMA to activate the proenzymatic forms. Panel A. NF: normal fibrob-
lasts, DF: desmoid fibroblasts, DFT: desmoid fibroblasts plus toremifene. In the same zymogram an aliquot of samples was 
activated with APMA: NF: normal fibroblasts, DF: desmoid fibroblasts, DFT: desmoid fibroblasts plus toremifene, C: trypsin. 
Similar results were obtained in four separate experiments. Panel B. The absolute counts, obtained by densitometric analysis, 
were converted to percentages assuming the level of normal fibroblasts as 100%. Gelatin zymogram. One set of samples was 
treated with APMA to activate the proenzymatic forms. Panel C. NF: normal fibroblasts, DF: desmoid fibroblasts, DFT: 
desmoid fibroblasts plus toremifene. In the same zymogram an aliquot of samples was activated with APMA: NF: normal fibrob-
lasts, DF: desmoid fibroblasts, DFT: desmoid fibroblasts plus toremifene. Similar results were obtained in four separate experi-
ments. Panel D. The absolute counts, obtained by densitometric analysis, were converted to percentages assuming the level of 
normal fibroblasts as 100%.
A. 
Non activated Activated   
 with APMA  
NF DF DFT NF DF DFT C 
                                         
B. 
 Non activated Activated  
with APMA 
Normal fibroblasts 100 100
Desmoid fibroblasts 235 236 
Desmoid fibroblasts plus 
toremifene 
257 233 
C. 
Non activated Activated  
 with APMA 
NF DF DFT NF DF DFT 
                                        
D. 
Non activated Activated with 
APMA 
MMP-2 MMP-9 MMP-2 MMP-9 
Normal fibroblasts 100 100 100 100
Desmoid fibroblasts 195 97 261 105 
Desmoid fibroblasts plus toremifene 259 102 251 98 
MMP-9    92 kDa→
MMP-2    66 kDa→
MMP-1    52 kDa →Page 9 of 14
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Western blot analysis of MMP-1, MMP-2, MMP-9 secreted into the medium. Panel A: MMP-1; panel B: MMP-2; panel 
C: MMP-9. The samples are as follows: NF, normal fibroblasts; DF, desmoid fibroblasts; DFT, desmoid fibroblasts plus 
toremifene. Similar results were obtained in four separate experiments. Panel D. The absolute counts, obtained by densitomet-
ric analysis, were converted to percentages assuming the level of normal fibroblasts as 100%. ND = not determined.
A. 
NF DF DFT 
                                                          
B. 
NF DF DFT
C. 
NF DF DFT 
D. 
MMP-1 MMP-2 MMP-9 
Normal fibroblasts 100 100 100 
Desmoid fibroblasts 200 220 91 
Desmoid fibroblasts plus toremifene 223 332 97 
MMP-1   52 kDa →
MMP-2   72 kDa→
                66 kDa→
MMP-9   92 kDa→Page 10 of 14
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No significant differences emerged in the production of
MMP-9 (Fig. 5, panel C).
Western-blot analysis of TIMP-1 and TIMP-2
Western blot analysis showed that desmoid fibroblasts
produced about 7.2 and 3.4 fold TIMP-1 (Fig. 6, panel A)
and TIMP-2 respectively (Fig. 6, panel B) than normal
fibroblasts. Adding toremifene to desmoid fibroblasts
decreased TIMP-1 by 18%, but had no effect on TIMP-2.
Discussion
Desmoid tumour is a benign non-invasive and non-
metastasising neoplasm with an abnormal ECM
macromolecule deposition which is stimulated by TGFβ1
[3,23,24]. The regulation of extracellular matrix dynamics
is clearly complicated, involving a balance between the
deposition of structural components such as collagen and
their degradation by MMPs, i.e. collagenases and gelati-
nases. MMP activity is itself regulated by a variety of mech-
anisms, including a requirement for enzyme modification
to elicit maximal enzymatic activity and the activity of
specific TIMPs [25]. There is now evidence that desmoid
cells undergo dramatic clinical response to toremifene,
implying the drug has a direct effect upon fibroblasts. Our
previous studies showed that toremifene significantly
inhibited TGFβ1 activity which was six fold higher in
desmoid than in normal fibroblasts [3]. As desmoid
tumour is also associated with abnormal collagen produc-
tion [26], in the present study we examined the rate of col-
lagen synthesis and degradation in the presence or
absence of toremifene. In our experimental conditions,
type I and III collagen accumulation in the intra- and
extra-cellular compartments showed no differences after 3
h of in vitro maintenance, but increased significantly
more after 24 and 48 h in desmoid fibroblasts than in nor-
mal fibroblasts. No increase in collagen after 3 hours sug-
gests its accumulation in desmoid fibroblasts is due to
inhibition of degradation rather than to increased synthe-
sis. The results are confirmed by procollagen α1 (I) gene
expression, which showed mRNA levels were only lower
in desmoid cells treated with toremifene. Normal and
desmoid fibroblasts expressed different amounts of
MMPs. Several studies suggest that MMPs are over-
expressed in malignant tumour progression and facilitate
both local tumour invasion and metastasis [27,28]. Dif-
ferent MMPs may play distinct roles at different stages of
tumour development [29]. They may form a network, in
which a single MMP is crucial for the cleavage of certain
native or partially degraded matrix components and for
the activation of other latent MMPs. MMP-1 plays a piv-
otal role in cancer progression and poor prognosis in
colon-rectal, oesophageal and gastric cancer has been cor-
related with high MMP-1 expression [25,30]. Nishiota
[31] showed MMP-1 is expressed more strongly in the
cancer front of invasion. MMP-2 is increased in cancer tis-
sue and its over-expression is correlated with tumour-
related basement membrane degradation and vascular
invasion [32,33]. Therefore inhibition of the expression
or activity of only one MMP could potentially reduce per-
itumoural proteolytic activity and tumour invasion [34].
In this study we investigated the metalloproteinases most
involved in type I collagen degradation, i.e. MMP-1 (col-
lagenase-1), MMP-2 (gelatinase-A) and MMP-9 (gelati-
nase-B) and their natural inhibitors TIMP-1 and TIMP-2
[11]. Moreover TIMP-2 is 10-fold more potent than TIMP-
1 against MMP-2 [11] which is involved either in the final
degradation of native collagen or in the initial degrada-
tion cleaving native type I collagen to 3/4 and 1/4 frag-
ments identical to those generated by MMP-1 [12]. Using
Western blot we showed no differences in MMP-9 produc-
tion, while MMP-1 and MMP-2 were higher in desmoid
than in normal fibroblasts. Collagen and gelatin zymo-
grams, in which the proteolytic enzymes were separated
from TIMPs before the assay, proved the activities of col-
lagenase MMP-1 and gelatinase MMP-2, as dosed in
conditioned media, were higher in desmoid than in nor-
mal fibroblasts. However, collagenase activity, in the pres-
ence of TIMPs, was reduced in desmoid compared to
normal fibroblasts as shown by the lower amount of 3/4
and 1/4 fragments of fibrillar collagen in desmoid cells.
Together these results indicated the higher MMP-1 and
MMP-2 activity in desmoid cells was masked by a 7-fold
increase in TIMP-1 and a 3-fold increase in TIMP-2. TIMP-
1 is a potent inhibitor of apoptosis in many cells types, its
up-regulation protects the cells against apoptotic stimuli
[35]; hence, greater number of viable cells in desmoid
tumour.
Upregulation in both inhibitors of MMPs may explain
why the Desmoid tumour is characterised by an abundant
deposition of ECM macromolecules and is neither
malignant nor invasive. Toremifene addition to desmoid
fibroblasts reduced the accumulation of collagen fibres
but its mechanism of action remains unclear. Toremifene
increased MMP-1 and MMP-2 activity by 8% and 25%
respectively and decreased TIMP-1 by 18%. Despite these
modest effects type I collagen degradation in 3/4 and 1/4
fragments increased almost 4-fold.
Conclusion
Our previous studies showed that TGFβ1 was 6-fold higher
in desmoid than in normal fibroblasts and that
toremifene significantly reduced TGFβ1 activity and TGFβ1
membrane-receptors [3]. So the effects of toremifene on
MMPs and TIMPs could be linked to its effects on TGFβ1
because the growth factor enhances organic macromole-
cule accumulation in the ECM via a reduction in MMP-1
and MMP-2 [36] and an increase in TIMP-1 [37], so
favouring tumour mass growth through an inhibition ofPage 11 of 14
(page number not for citation purposes)
BMC Cancer 2005, 5:22 http://www.biomedcentral.com/1471-2407/5/22Western blot analysis of TIMP-1 and TIMP-2 secreted into the mediumFigure 6
Western blot analysis of TIMP-1 and TIMP-2 secreted into the medium. Panel A; TIMP-1. Panel B; TIMP-2. The sam-
ples are as follows: NF, normal fibroblasts; DF, desmoid fibroblasts; DFT, desmoid fibroblasts plus toremifene. Similar results 
were obtained in four separate experiments. Panel C. The absolute counts, obtained by densitometric analysis, were converted 
to percentages assuming the level of normal fibroblasts as 100%.
A. 
NF DF DFT 
B. 
NF      DF DFT 
C. 
TIMP-1 TIMP-2 
Normal fibroblasts 100 100
Desmoid fibroblasts 735 343 
Desmoid fibroblasts plus toremifene 603 358 
TIMP-1   30 kDa →
TIMP-2   18 kDa →Page 12 of 14
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BMC Cancer 2005, 5:22 http://www.biomedcentral.com/1471-2407/5/22ECM macromolecule degradation. In the light of these
data the reduction of organic macromolecules in the ECM
in the presence of toremifene can be ascribed to its inhibi-
tion not only of collagen synthesis, but also of TGFβ1
activity. Further studies on the regulation of MMP activi-
ties may clarify the role of toremifene on ECM degrada-
tion and provide important clues about pathogenesis of
desmoid tumour.
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